Cargando…

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production

The ErbB2 blocker trastuzumab improves survival in oncologic patients, but can cause cardiotoxicity. The late Na+ current inhibitor ranolazine has been shown to counter experimental HF, including doxorubicin cardiotoxicity (a condition characterized by derangements in redox balance), by lowering the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Riccio, Gennaro, Antonucci, Salvatore, Coppola, Carmela, D'Avino, Chiara, Piscopo, Giovanna, Fiore, Danilo, Maurea, Carlo, Russo, Michele, Rea, Domenica, Arra, Claudio, Condorelli, Gerolama, Di Lisa, Fabio, Tocchetti, Carlo G., De Lorenzo, Claudia, Maurea, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808165/ https://www.ncbi.nlm.nih.gov/pubmed/29467663 http://dx.doi.org/10.3389/fphys.2018.00038

Ejemplares similares

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
por: De Lorenzo, Claudia, et al.
Publicado: (2018)

Antineoplastic-related cardiotoxicity, morphofunctional aspects in a murine model: contribution of the new tool 2D-speckle tracking
por: Coppola, Carmela, et al.
Publicado: (2016)

Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
por: Riccio, Gennaro, et al.
Publicado: (2016)

Effect of Erdosteine on Cyclosporine Induced Chronic Nephrotoxicity
por: Briguori, Carlo, et al.
Publicado: (2012)

The Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization
por: Calcagno, Simone, et al.
Publicado: (2020)

Novel Biomarkers for Contrast-Induced Acute Kidney Injury
por: Briguori, Carlo, et al.
Publicado: (2014)

PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology
por: Quagliariello, Vincenzo, et al.
Publicado: (2023)

Management of differentiated thyroid cancer through nuclear medicine facilities during Covid-19 emergency: the telemedicine challenge
por: Klain, Michele, et al.
Publicado: (2020)

Update on ranolazine in the management of angina
por: Codolosa, J Nicolás, et al.
Publicado: (2014)

Ranolazine for Angina in Hypertrophic Cardiomyopathy
por: Amin, Akhtar, et al.
Publicado: (2018)

Ranolazine: A Contemporary Review
por: Rayner‐Hartley, Erin, et al.
Publicado: (2016)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
por: Maurea, Nicola, et al.
Publicado: (2016)

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology
por: Spallarossa, Paolo, et al.
Publicado: (2016)

Improving adherence rates to a cocooning program: A pilot experience in Italy
por: Simonetti, Andrea, et al.
Publicado: (2013)

Second Primary Malignancies in Patients with Differentiated Thyroid Cancer after Radionuclide Therapy: A Retrospective Single-Centre Study
por: Piscopo, Leandra, et al.
Publicado: (2022)

Nano-Encapsulation of Coenzyme Q10 in Secondary and Tertiary Nano-Emulsions for Enhanced Cardioprotection and Hepatoprotection in Human Cardiomyocytes and Hepatocytes During Exposure to Anthracyclines and Trastuzumab
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

A Rare Neurological Complication of Ranolazine
por: Porhomayon, Jahan, et al.
Publicado: (2013)

Renal phospholipidosis possibly induced by ranolazine
por: Scheurle, Christoph, et al.
Publicado: (2014)

Improvement of Vascular Insulin Sensitivity by Ranolazine
por: Guerra-Ojeda, Sol, et al.
Publicado: (2023)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
por: Quagliariello, Vincenzo, et al.
Publicado: (2020)

The new era of advanced placental tissue characterization using MRI texture analysis: Clinical implications
por: Romeo, Valeria, et al.
Publicado: (2019)

Cardioprotective Effects of Nanoemulsions Loaded with Anti-Inflammatory Nutraceuticals against Doxorubicin-Induced Cardiotoxicity
por: Quagliariello, Vincenzo, et al.
Publicado: (2018)

Utility of ranolazine in chronic stable angina patients
por: Patel, Pawan D, et al.
Publicado: (2008)

Emerging clinical role of ranolazine in the management of angina
por: Vadnais, David S, et al.
Publicado: (2010)

Refractory atrial fibrillation effectively treated with ranolazine
por: Vaishnav, Aditi, et al.
Publicado: (2014)

Effects of Ranolazine on Astrocytes and Neurons in Primary Culture
por: Aldasoro, Martin, et al.
Publicado: (2016)

Keratolysis exfoliativa-like eruption induced by ranolazine
por: Pierobon, Elena, et al.
Publicado: (2022)

Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics—A Systematic Review
por: Brancato, Valentina, et al.
Publicado: (2020)

The Role of RNA and DNA Aptamers in Glioblastoma Diagnosis and Therapy: A Systematic Review of the Literature
por: Nuzzo, Silvia, et al.
Publicado: (2020)

miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS
por: Fiore, Danilo, et al.
Publicado: (2016)

The True Value of Quantitative Imaging for Adrenal Mass Characterization: Reality or Possibility?
por: Stanzione, Arnaldo, et al.
Publicado: (2023)

Ranolazine Attenuates Brain Inflammation in a Rat Model of Type 2 Diabetes
por: Cassano, Velia, et al.
Publicado: (2022)

Mechanism of action of the new anti-ischemia drug ranolazine
por: Hasenfuss, G., et al.
Publicado: (2007)

Safety and Efficacy of Ranolazine for the Treatment of Chronic Angina Pectoris
por: Aldakkak, Mohammed, et al.
Publicado: (2013)

Anti-adrenergic effects of ranolazine in isolated rat aorta
por: Marchio, P, et al.
Publicado: (2014)

Ranolazine can markedly increase tacrolimus blood levels
por: Seck, Sidy, et al.
Publicado: (2011)

Impact of ranolazine on ventricular arrhythmias – A systematic review
por: Bazoukis, George, et al.
Publicado: (2018)

COVID-19-related arrhythmias and the possible effects of ranolazine
por: Chukwunyere, Ugochukwu, et al.
Publicado: (2021)

Ranolazine - could an antianginal drug be used in stroke prevention?
por: Surma, Stanisław, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_drpk13t0vh579lsusa6uqcc73q